For the roughly 6 million people worldwide living with Down syndrome, Alzheimer's disease is not a risk — it is near-certain. Virtually all adults with trisomy 21 develop amyloid and tau pathology, typically decades earlier than the general population. As amyloid-clearing therapies enter clinical use, the urgency of detecting disease at its earliest biological inflection point has never been greater — and this study offers a meaningful advance in that effort.
Drawing on 328 participants enrolled in the Alzheimer Biomarker Consortium–Down Syndrome cohort, researchers used longitudinal amyloid PET (both cortical and striatal), tau PET, and plasma phosphorylated tau at threonine-217 (pTau217) to sequence the order in which pathological changes emerge. Using generalized additive mixed models anchored to chronological age, they found that striatal amyloid accumulation precedes cortical amyloid deposition — a sequencing that diverges from typical late-onset Alzheimer's progression. Critically, plasma pTau217 was able to identify not only the current presence of amyloid and tau pathology but also to predict future accumulation, suggesting it may serve as a minimally invasive sentinel biomarker for early-stage disease in this population.
This work sits at a productive intersection of two fast-moving fields: Down syndrome Alzheimer's research and the emerging clinical deployment of blood-based Alzheimer's biomarkers. The pTau217 signal has gained substantial momentum across late-onset Alzheimer's literature as well, lending biological plausibility to its utility here. A key limitation is that the cohort, while sizeable for this rare population, is still relatively small for deriving generalizable diagnostic thresholds, and receiver-operating-characteristic-derived cutoffs will require external validation. The finding of striatal-first amyloid accumulation is also intriguing mechanistically and warrants replication. Overall, this represents a substantive, clinically actionable contribution that could directly inform enrollment criteria for upcoming therapeutic trials in trisomy 21 — making it more than incremental.